Compare AA & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AA | EXEL |
|---|---|---|
| Founded | 1888 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aluminum | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 12.7B |
| IPO Year | 2016 | 2000 |
| Metric | AA | EXEL |
|---|---|---|
| Price | $46.89 | $57.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 21 |
| Target Price | ★ $67.20 | $46.50 |
| AVG Volume (30 Days) | ★ 3.1M | 1.8M |
| Earning Date | 04-16-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 1580.77 | 57.95 |
| EPS | ★ 3.13 | 1.60 |
| Revenue | ★ $12,831,000,000.00 | $452,477,000.00 |
| Revenue This Year | $16.05 | $13.61 |
| Revenue Next Year | N/A | $13.13 |
| P/E Ratio | ★ $14.86 | $35.56 |
| Revenue Growth | ★ 7.87 | N/A |
| 52 Week Low | $30.81 | $33.76 |
| 52 Week High | $84.38 | $59.72 |
| Indicator | AA | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 53.84 |
| Support Level | $46.01 | $54.30 |
| Resistance Level | $54.19 | $57.12 |
| Average True Range (ATR) | 1.73 | 1.54 |
| MACD | -0.49 | -0.04 |
| Stochastic Oscillator | 5.39 | 55.18 |
Alcoa is a vertically integrated aluminum company whose operations include bauxite mining, alumina refining, and manufacturing primary aluminum. It is one of the world's largest bauxite miners and alumina refiners by production volume, but sits outside the top-10 aluminum producers, a list dominated by Chinese companies. Profits are closely tied to prevailing commodity prices along the aluminum supply chain.Alcoa was the first mass producer of aluminum, launching the world-changing Hall-Heroult smelting process in the 1880s, making aluminum affordable. It listed as a public company in 1925. In 2016, Alcoa spun off its automotive and aerospace metal parts segment to focus on mining, smelting, and refining. It bought the 40% unowned balance of AWAC in mid-2024.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.